VALBY, Denmark, July 23, 2026
Lundbeck has received U.S. Food and Drug Administration (FDA) Fast Track designation for Lu AH69593, its investigational oral orexin 2 receptor (OX2R) agonist being developed for the treatment of narcolepsy. The designation marks a significant regulatory milestone for the company as it advances a pipeline of innovative therapies targeting sleep-wake disorders and reinforces the potential of orexin biology to address one of the most debilitating neurological conditions. Currently in Phase 1b clinical development, Lu AH69593 is designed to activate the orexin 2 receptor, a critical component of the biological pathway responsible for maintaining wakefulness and regulating the sleep-wake cycle. By directly targeting the underlying mechanism disrupted in narcolepsy, the investigational therapy has the potential to provide a disease-focused treatment approach beyond current symptom-management strategies, offering new hope for patients living with excessive daytime sleepiness and other life-altering symptoms.
FDA Fast Track Designation Accelerates Development
The FDA Fast Track designation is granted to investigational medicines intended to treat serious conditions while addressing significant unmet medical needs. The designation enables closer collaboration between the FDA and drug developers, with opportunities for more frequent regulatory interactions, rolling submission of marketing applications, and potentially faster review timelines if clinical data continue to support development. For Lundbeck, the recognition represents an important step in expanding its neuroscience pipeline beyond psychiatry into neurology, neuroendocrinology, and rare neurological disorders. Company leadership emphasized that the designation reflects both the urgent need for innovative therapies for narcolepsy and the scientific promise of Lu AH69593. The company believes advancing orexin-based therapies could transform the treatment landscape by restoring normal wakefulness through mechanisms directly linked to the disease rather than simply reducing symptoms.
Novel Orexin Therapy Targets the Root Cause of Narcolepsy
Narcolepsy is a chronic neurological disorder characterized by impaired regulation of sleep and wakefulness, resulting in excessive daytime sleepiness, sudden sleep attacks, fragmented nighttime sleep, hallucinations, sleep paralysis, and, in narcolepsy type 1, episodes of cataplexy, a sudden loss of muscle control triggered by emotions. The condition significantly impacts education, employment, social interaction, and overall quality of life. Lu AH69593 is a small-molecule oral orexin 2 receptor agonist developed to restore activity within the orexin signaling pathway, which plays a central role in maintaining wakefulness. In patients with narcolepsy, disruption of orexin signaling contributes directly to the disorder’s hallmark symptoms. By selectively activating the OX2R receptor, Lu AH69593 is designed to restore normal sleep-wake regulation and improve daytime alertness. The investigational therapy is currently undergoing Phase 1b clinical evaluation, where researchers are assessing its safety, tolerability, pharmacokinetics, and pharmacodynamics.
Advertisement
Lundbeck Strengthens Leadership in Brain Health Innovation
The Fast Track designation further strengthens Lundbeck’s strategic commitment to developing transformative therapies for brain disorders, an area where the company has focused for more than seven decades. As scientific understanding of neurological diseases continues to advance, Lundbeck is expanding its research portfolio into rare neurological diseases, sleep disorders, and specialized neuroscience indications where treatment options remain limited. The company’s investment in orexin receptor agonists reflects growing confidence that therapies targeting the biological drivers of disease may offer more meaningful and durable clinical benefits than conventional symptomatic treatments. With Lu AH69593 progressing through clinical development and receiving regulatory recognition from the FDA, Lundbeck continues to position itself at the forefront of neuroscience innovation, aiming to deliver new treatment options that improve the daily lives of patients affected by chronic sleep-wake disorders and other complex neurological conditions.
Source: Lundbeck press release
